Results 31 to 40 of about 2,458 (69)

Clinical Evaluation of Meropenem-Vaborbactam Combination for the Treatment of Urinary Tract Infection: Evidence to Date. [PDF]

Infect Drug Resist, 2023
Herald F, Burgos RM.
europepmc   +1 more source

Meropenem-Vaborbactam for Treatment of Carbapenem-Resistant Enterobacterales: A Narrative Review of Clinical Practice Evidence. [PDF]

Infect Dis Ther
Bassetti M, Giacobbe DR, Vena A, Poulakou G, Rossolini GM, Soriano A, Nicolau DP.   +6 more
europepmc   +1 more source

Continuous infusion of meropenem-vaborbactam for a KPC-3-producing Klebsiella pneumoniae bloodstream infection in a critically ill patient with augmented renal clearance. [PDF]

Infection, 2023
Larcher R, Laffont-Lozes P, Naciri T, Bourgeois PM, Gandon C, Magnan C, Pantel A, Sotto A.   +7 more
europepmc   +1 more source

Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant Enterobacterales Strains, Including Carbapenem-Resistant Isolates. [PDF]

Microbiol Spectr, 2023
Shortridge D, Kantro V, Castanheira M.
europepmc   +1 more source

Mutations in ompK36 differentially impact in vitro synergy of meropenem/vaborbactam and ceftazidime/avibactam in combination with other antibiotics against KPC-producing Klebsiella pneumoniae. [PDF]

JAC Antimicrob Resist, 2023
Rogers TM, Kline EG, Griffith MP, Jones CE, Rubio AM, Squires KM, Shields RK.   +6 more
europepmc   +1 more source

National Cohort of Compassionate Use of Meropenem-Vaborbactam: No Benefit over Meropenem for Pseudomonas aeruginosa. [PDF]

Antibiotics (Basel)
Dinh A, Bleibtreu A, Duran C, Bouchand F, Bosch A, Crozon-Clauzel J, Roncato-Saberan M, Matt M, Boibieux A, Fanton A, Wille H, Fiaux E, Pilmis B, Lacoste M, Saint-Genis Q, Thumerelle C, Pavese P, Vuotto F, Senneville E, Potron A, Corvec S, Boutoille D, Jeannot K, Dortet L, On Behalf Of The Meropenem-Vaborbactam French Study Group.   +24 more
europepmc   +1 more source

Clonal dissemination of Klebsiella pneumoniae resistant to cefiderocol, ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam co-producing KPC and OXA-181 carbapenemase. [PDF]

JAC Antimicrob Resist, 2023
Bovo F, Amadesi S, Palombo M, Lazzarotto T, Ambretti S, Gaibani P.   +5 more
europepmc   +1 more source

Population pharmacokinetics of meropenem-vaborbactam in acutely ill hospitalized patients with various degrees of renal dysfunction including continuous renal replacement therapy. [PDF]

Antimicrob Agents Chemother
Reed G, Valadez A, Smith BJ, McCreary EK, Kline EG, Neely MN, Squires KM, Shields RK, Rhodes NJ.   +8 more
europepmc   +1 more source

TDM-guided meropenem/vaborbactam-based therapy for successful treatment of intra-abdominal and bloodstream infection caused by KPC-producing ceftazidime/avibactam-resistant Klebsiella pneumoniae in a paediatric liver transplant recipient. [PDF]

J Antimicrob Chemother
Mulé G, Coniglione G, Gatti M, Cona A, Di Martino G, Ranucci G, de Ville de Goyet J, Pea F, Mularoni A.   +8 more
europepmc   +1 more source

Head-to-head: meropenem/vaborbactam versus ceftazidime/avibactam in ICUs patients with KPC-producing K. pneumoniae infections- results from a retrospective multicentre study. [PDF]

Infection
Marino A, Maraolo AE, Mazzitelli M, Oliva A, Geremia N, De Vito A, Gullotta C, Scaglione V, Vania E, Lo Menzo S, Navalesi P, Volpicelli L, Fiori A, Prestifilippo P, Cattelan A, Mastroianni CM, Madeddu G, Cacopardo B, Nunnari G.   +18 more
europepmc   +1 more source